The immunopeptidome is the set of peptides presented by the major histocompatibility
complex (MHC) molecules, in humans also known as the human leukocyte antigen (HLA) …

The repertoire of naturally presented peptides within the MHC (major histocompatibility
complex) or HLA (human leukocyte antigens) system on the cellular surface of every …

It has been intensively reported that the immunosuppressive tumor microenvironment (TME)
results in tumor resistance to immunotherapy, especially immune checkpoint blockade and …

Central to successful cancer immunotherapy is effective T cell antitumor immunity. Multiple
targeted immunotherapies engineered to invigorate T cell-driven antitumor immunity rely on …

Biological therapies have changed the face of oncology by targeting cancerous cells while
reducing the effect on normal tissue. This publication focuses mainly on new therapies that …

Oncolytic viruses are naturally occurring or genetically engineered viruses that can replicate
preferentially in tumor cells and inhibit tumor growth. These viruses have been considered …

Simple Summary This review provides a roadmap to develop safe and effective OV-based
future therapeutics by using several novel synthetic and system biology strategies …

Immunotherapy with neoantigens presented by major histocompatibility complex (MHC) is
one of the most promising approaches in cancer treatment. Using this approach, cancer …

Major histocompatibility complex class I (MHC I) plays a crucial role in the development of
adaptive immune response in vertebrates. MHC molecules are cell surface protein …

Hepatocellular carcinoma (HCC) is one of the most lethal cancer types, and treatment
options for patients with advanced-stage HCC are limited. Neoantigens are newly …